DMTs During Pregnancy in Women with MS Do Not Affect Relapse Rates in Postpartum Periods
In this MEDtalk, Lene von Kappelgaard answers the question, does disease-modifying therapy during pregnancy affect the relapse rate in the postpartum period in women with MS? At ECTRIMS 2024, she presents her study aimed at exploring whether using DMTs during pregnancy affects postpartum relapse rates, especially those receiving fertility treatments, compared to pre-pregnancy or pregnancy periods.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in